Choice of optimal antihypertensive therapy in patients with diabetes mellitus type 2
- Authors: Tsvetkov V.A.1, Krutikov E.S.1, Chistyakova S.I.1
-
Affiliations:
- Medical Academy named after S.I. Georgievsky of Vernadsky Crimean Federal University
- Issue: Vol 7, No 4 (2021)
- Pages: 62-69
- Section: INNOVATIVE DEVELOPMENT OF METHODS OF DIAGNOSIS AND TREATMENT OF DISEASES
- Submitted: 04.01.2022
- Accepted: 04.01.2022
- Published: 04.01.2022
- URL: https://seamed.bmoc-spb.ru/jour/article/view/524
- DOI: https://doi.org/10.22328/2413-5747-2021-7-4-62-69
- ID: 524
Cite item
Full Text
Abstract
Aim of the study: to develop personalized approaches to combined antihypertensive therapy in patients with type 2 diabetes mellitus and arterial hypertension, depending on the parameters of the daily blood pressure profile and heart rate variability.
Material and methods. We examined 322 patients with type 2 diabetes and arterial hypertension who had not previously received antihypertensive drugs on a regular basis. At the first stage, patients were prescribed Perindopril 10 mg per day and Indapamide retard 1,5 mg per day. In the absence of reaching target blood pressure (BP) levels after 28 days, a third antihypertensive drug was added — Amlodipine 5 mg per day, followed by titration to 10 mg 1 r per day (group I) or a b-blocker — Carvedilol at a dose of 12,5 mg 2 r per day, also followed by titration up to 25 mg 2 r per day (group II). Daily monitoring of BP and ECG was carried out, the average daily heart rate (HR), circadian index (CI), as well as heart rate variability were determined.
Results and its discussion. Patients with type 2 diabetes have a high variability of blood pressure throughout the day, high pulse blood pressure, as well as a rigid circadian profile of heart rate. The appointment of a standard two-component antihypertensive therapy, including Perindopril 10 mg and Indapamide retard 1,5 mg per day, allows reaching the target blood pressure only in 46% of patients. The addition of amlodipine or carvedilol significantly increases the effectiveness of therapy, allowing more than 80% of patients to achieve the target blood pressure. At the same time, the use of amlodipine leads to a greater extent to a decrease in pulse pressure, and the inclusion of carvedilol improves the circadian profile of blood pressure and heart rate, and has a positive effect on heart rate variability.
Keywords
About the authors
V. A. Tsvetkov
Medical Academy named after S.I. Georgievsky of Vernadsky Crimean Federal University
Author for correspondence.
Email: vlaltsvetkov@gmail.com
Simferopol
Russian FederationE. S. Krutikov
Medical Academy named after S.I. Georgievsky of Vernadsky Crimean Federal University
Email: neprostar@yandex.ru
Simferopol
Russian FederationS. I. Chistyakova
Medical Academy named after S.I. Georgievsky of Vernadsky Crimean Federal University
Email: sve-chistyakova@yandex.ru
Simferopol
Russian FederationReferences
- Hippisley-Cox J., Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all-cause mortality: cohort study in primary care // BMJ. 2016. Vol. 354. Р. i3477. https://doi.org/10.1136/bmj.i3477.
- Shah A. D., Langenberg C., Rapsomaniki E., Denaxas S., Pujades-Rodriguez M., Gale C. P. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1,9 million people // The Lancet Diabetes & Endocrinology. 2015. Vol. 3, No. 2. Р. 105–113. https://doi.org/10.1016/S2213-8587(14)70219-0.
- Safar M.E., Gnakaméné J.B., Bahous S.A. Longitudinal Study of Hypertensive Subjects With Type 2 Diabetes Mellitus: Overall and Cardiovascular Risk // Hypertension. 2017. Vol. 69, No. 6. Р.102935. https://doi.org/10.1161/hypertension.aha.116.08962.
- Fan W. Epidemiology in diabetes mellitus and cardiovascular disease // Cardiovascular Endocrinology. 2017. Vol. 6, No. 1. Р. 81635. https://doi.org/10.1097/XCE.0000000000000116.
- Dei Cas A., Khan S.S., Butler J. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure // JACC Heart Fail. 2015. Vol. 3, No. 2. Р. 136145. https://doi.org/10.1016/j.jchf.2014.08.004.
- Кобалава Ж.Д., Ешниязов Н.Б., Медовщиков В.В., Хасанова Э.Р. Сахарный диабет 2 го типа и сердечная недостаточность: инновационные возможности управления прогнозом // Кардиология. 2019. Т. 59, № 4. С. 76–87.
- Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным са- харным диабетом. М., 2019.
- 2018 ESC/ESH Guidelines for the management of arterial hypertension // EHJ. 2018. Vol. 39. Р. 3021104.https://doi.org/10.1093/eurheartj/ehy339.
- Tahrani A.A., Barnett A.H., Bailey C.J. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus // Nature Reviews Endocrinology. 2016. Vol. 12, No. 10. Р. 56692. https://doi.org/10.1038/nrendo.2016.86.